Professor Daniel Gale is a distinguished nephrologist who trained at Cambridge University and pursued postgraduate training in Nephrology in London, completing a PhD under the mentorship of Patrick Maxwell. Since 2018, he has held the St Peter’s Chair of Nephrology at University College London (UCL), where he leads the Centre for Genetics and Genomics in the Department of Renal Medicine.
Professor Gale is a pioneer in the field of renal genetics. He established and currently runs the North/Central London Renal Genetics Service, providing expert care for patients and families with rare kidney diseases such as polycystic kidney disease, C3 glomerulopathy, and Alport syndrome. His clinic emphasizes both genomic testing and cutting-edge research, including observational and interventional studies, with a focus on clinical trials for potential new treatments for rare kidney diseases.
A key figure in the discovery of HIF2α erythrocytosis with pulmonary hypertension and CFHR5 nephropathy, Professor Gale identified the genetic basis of these diseases, advancing understanding of oxygen sensing defects and conditions endemic to specific populations, such as Cypriots.
Professor Gale’s research group utilizes large-scale genomics to further the understanding of various kidney diseases, including C3 glomerulopathy, nephrotic syndrome, posterior urethral valves, intrahepatic cholestasis of pregnancy, and IgA nephropathy. His work has significantly contributed to the genetics of kidney disease, providing new insights into these complex conditions.
As Director of RaDaR, the UK Rare Kidney Disease Registry, Professor Gale leads efforts involving over 30,000 patients across more than 100 hospitals. His team has uncovered valuable epidemiological data, including the lifetime risks of kidney failure or death for 20 rare renal conditions.
Professor Gale also chairs the Therapeutic Innovation and Clinical Trials Genomics England (GEL) Research Network and leads the renal GEL clinical interpretation partnership. His efforts have been instrumental in integrating genomic testing into mainstream NHS care, helping to revolutionize the diagnosis and treatment of rare kidney diseases.
